South China Morning Post CENTER (0.0) Reliability: 7.5/10

Singapore’s Nanyang Biologics to list on Nasdaq amid Trump’s tariffs on pharma imports

✍️ Julie Zhang 📅 October 13, 2025 08:30 PM 🕐 Scraped: October 13, 2025

Summary: The start-up agrees to merge with a special-purpose acquisition company in a deal that puts its value at US$1.5 billion.

“The US administration wants intellectual property owners to manufacture in the US, including drugs,” founder Roland Ong said on Monday.

📰

Continue Reading on South China Morning Post

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →

How do you feel about this article?

Read Original Article →

📝 Article Information

Author

Julie Zhang

Original Publisher

🌍 South China Morning Post

CENTER Bias (0.0)

Published Date

October 13, 2025 at 08:30 PM

ℹ️

Disclaimer

ArkforgeAI.com - Newsource is a news aggregation platform. We do not create, write, or produce original news content. All articles are sourced from their respective publishers and remain the property of their original creators. We analyze and aggregate news from multiple sources to provide diverse perspectives across the political spectrum.

The content displayed here is for informational purposes only. For the complete and original article, please visit the source's website using the "Read Original Article" link above.

Desktop Only